Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Brand-name Ozempic in Canada costs CAD $250 to $315 per month without insurance, varying by province and pharmacy markup
- Public provincial drug plans cover Ozempic only for type 2 diabetes with specific HbA1c thresholds, not for weight loss
- Private insurance coverage averages 60% to 80% reimbursement after deductibles, with prior authorization required in most plans
- U.S. compounded semaglutide through telehealth platforms costs USD $297 to $399 monthly (CAD $405 to $545), often less expensive than Canadian out-of-pocket pricing after accounting for cross-border logistics
Direct answer (40-60 words)
Ozempic costs CAD $250 to $315 per month in Canada without insurance. Provincial public plans cover it only for type 2 diabetes meeting specific criteria. Private insurance typically covers 60% to 80% after prior authorization. U.S. compounded semaglutide costs USD $297 to $399 monthly, which translates to CAD $405 to $545 at April 2026 exchange rates.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The baseline price: what Ozempic costs at Canadian pharmacies
- Provincial public drug plan coverage: who qualifies and who doesn't
- Private insurance coverage patterns and prior authorization requirements
- The out-of-pocket calculation for weight loss vs diabetes
- What most articles get wrong about Canadian drug pricing
- Cross-border comparison: U.S. compounded semaglutide vs Canadian brand-name
- The decision tree: when to pursue Canadian coverage vs alternatives
- Manufacturer patient assistance programs in Canada
- Provincial cost breakdown table
- The 2026 coverage shift: what changed with obesity recognition
- When cross-border telehealth makes financial sense
- FAQ
The baseline price: what Ozempic costs at Canadian pharmacies
Ozempic's list price in Canada is set by Novo Nordisk and varies by dose strength. As of April 2026, the manufacturer's suggested retail pricing is:
- 0.25 mg / 0.5 mg starter pack (4 doses): CAD $250 to $270
- 1 mg maintenance pack (4 doses): CAD $285 to $305
- 2 mg maintenance pack (4 doses): CAD $295 to $315
The range reflects provincial pharmacy markup regulations. Quebec has the tightest markup caps (8% to 9%), while Alberta and British Columbia allow 12% to 15% markup on specialty medications. Ontario falls in the middle at 10%.
A patient on the standard 1 mg weekly maintenance dose pays approximately CAD $290 per month at a typical pharmacy. This is the out-of-pocket cost before any insurance or public plan coverage.
For comparison, the same 1 mg dose in the United States has a list price of USD $935 to $968 per month without insurance. Canada's regulated pricing structure keeps brand-name Ozempic significantly cheaper than U.S. cash pricing, which is why cross-border pharmaceutical tourism historically flowed north.
That pattern reversed in 2024 when U.S. compounded semaglutide became widely available through telehealth platforms at USD $297 to $399 monthly. The price inversion created a new calculus for Canadian patients paying out of pocket.
Provincial public drug plan coverage: who qualifies and who doesn't
Every Canadian province operates a public drug plan, but coverage criteria for Ozempic vary dramatically. The common thread: all provinces cover Ozempic for type 2 diabetes under specific conditions. None cover it for weight loss alone as of April 2026.
Ontario Drug Benefit (ODB)
Covers Ozempic for patients with type 2 diabetes who meet all of:
- HbA1c ≥ 7.5% despite metformin monotherapy
- BMI ≥ 30 or BMI ≥ 27 with cardiovascular risk factors
- Age 65+ or on social assistance or disability support
Out-of-pocket cost after coverage: CAD $2 to $6.11 per prescription (low-income seniors pay $2, others pay up to the deductible cap).
Quebec RAMQ
Covers Ozempic for type 2 diabetes patients with:
- HbA1c ≥ 7.0% on metformin plus one other oral agent
- Documented cardiovascular disease or chronic kidney disease
Monthly patient contribution: CAD $0 to $92 depending on income (maximum monthly contribution cap is $92 for all medications combined).
British Columbia PharmaCare
Covers Ozempic under Fair PharmaCare for type 2 diabetes with:
- HbA1c ≥ 7.5% despite two oral agents
- Special Authority approval required
Patient pays 30% of cost up to family maximum (typically CAD $2,000 to $3,000 annually depending on income). After maximum, coverage is 100%.
Alberta Blue Cross
Covers Ozempic for type 2 diabetes with:
- HbA1c ≥ 8.5% despite metformin
- Prior authorization required
Seniors and low-income residents pay 30% copay (CAD $87 per month). Others pay full cost until hitting the annual deductible (CAD $25 per family).
Other provinces
Saskatchewan, Manitoba, Nova Scotia, New Brunswick, Newfoundland, and PEI all have similar restrictive criteria requiring documented diabetes, elevated HbA1c despite oral medications, and prior authorization. Coverage for weight loss without diabetes diagnosis: zero provinces as of April 2026.
The pattern is consistent: public plans treat Ozempic as a third-line diabetes medication, not a weight-loss drug. If you don't have type 2 diabetes or your HbA1c is well-controlled, public coverage doesn't apply.
Private insurance coverage patterns and prior authorization requirements
Approximately 67% of Canadians have private insurance through employer-sponsored plans (Canadian Life and Health Insurance Association data, 2025). Coverage for Ozempic varies by insurer and plan tier.
Common private insurance patterns:
Tier 1 plans (executive and public sector):
- Cover Ozempic for both type 2 diabetes and weight loss (BMI ≥ 30 or BMI ≥ 27 with comorbidities)
- Require prior authorization documenting 6-month diet and exercise attempt
- Reimburse 80% to 90% after deductible
- Annual maximum: typically CAD $3,000 to $5,000 for GLP-1 medications
Tier 2 plans (standard employer coverage):
- Cover Ozempic for type 2 diabetes only
- Weight loss coverage varies (approximately 40% of plans added obesity coverage in 2025-2026)
- Reimburse 60% to 80% after deductible
- Annual maximum: CAD $2,000 to $3,000
Tier 3 plans (small business and individual):
- Cover Ozempic for diabetes with prior authorization
- Weight loss coverage rare (less than 20% of plans)
- Reimburse 50% to 70%
- Annual maximum: CAD $1,500 to $2,000
Prior authorization typically requires:
- Documented BMI ≥ 30 (or ≥ 27 with hypertension, dyslipidemia, or sleep apnea)
- Failed 6-month supervised diet and exercise program
- Prescribing physician letter outlining medical necessity
- Baseline labs (HbA1c, lipid panel, liver function)
Approval timelines range from 3 to 14 business days. Denial rates for weight loss indications run approximately 30% to 40% even when criteria are met, based on insurer discretion around "medical necessity."
The practical outcome: if you have type 2 diabetes, private insurance usually covers 60% to 80% of Ozempic cost. If you're using it for weight loss, coverage is inconsistent and often requires appeals.
The out-of-pocket calculation for weight loss vs diabetes
The financial picture changes dramatically based on your diagnosis and insurance status.
Scenario 1: Type 2 diabetes, public plan eligible (Ontario senior)
- Monthly Ozempic cost: CAD $290
- ODB coverage: pays all but CAD $2 copay
- Out-of-pocket: CAD $2/month or CAD $24/year
Scenario 2: Type 2 diabetes, private insurance (standard tier)
- Monthly cost: CAD $290
- Insurance covers 70% after CAD $500 annual deductible
- Out-of-pocket year 1: CAD $500 + (CAD $290 × 12 × 30%) = CAD $1,544
- Out-of-pocket year 2+: CAD $1,044/year
Scenario 3: Weight loss, no diabetes, private insurance denies
- Monthly cost: CAD $290
- Out-of-pocket: CAD $3,480/year
Scenario 4: Weight loss, exploring U.S. compounded semaglutide
- Monthly cost: USD $297 to $399 (CAD $405 to $545 at April 2026 exchange rate)
- Out-of-pocket: CAD $4,860 to $6,540/year
- Additional costs: cross-border shipping (USD $25 to $45/month), potential customs delays
The math flips based on insurance status. With good private coverage for diabetes, Canadian Ozempic is cheaper. Without coverage or for weight loss, the pricing gap narrows significantly, and some patients find U.S. compounded options competitive once factoring in prior authorization hassles and denial risk.
What most articles get wrong about Canadian drug pricing
Most U.S.-based articles about Canadian Ozempic pricing make the same error: they cite the manufacturer's list price (CAD $250 to $315) and conclude Canada is dramatically cheaper than the U.S. without accounting for three critical factors.
Error 1: Ignoring coverage eligibility.
The CAD $290 monthly price is only relevant if you're paying out of pocket. Most Canadians with type 2 diabetes access public or private coverage, which reduces their cost to CAD $2 to $100 per month. The articles compare Canadian list price to U.S. list price (USD $935), which almost no American pays either. The correct comparison is Canadian out-of-pocket after coverage vs U.S. out-of-pocket after coverage or compounded alternatives.
Error 2: Assuming weight-loss patients can access Canadian pricing.
Canadian public plans don't cover Ozempic for weight loss. Private insurance coverage is inconsistent. A U.S. patient reading "Ozempic is CAD $290 in Canada" and thinking they can access that price for weight loss is wrong. They'd need a Canadian prescription for type 2 diabetes, which requires meeting diagnostic criteria and having a Canadian prescriber, which requires being a Canadian resident or navigating medical tourism logistics.
Error 3: Overlooking the 2024-2026 compounded semaglutide price shift.
Articles written before mid-2024 correctly stated Canada was cheaper. That changed when U.S. compounding pharmacies began producing semaglutide at scale during the FDA shortage period. The current USD $297 to $399 compounded pricing (CAD $405 to $545) is within 40% to 90% of Canadian out-of-pocket pricing, and for some patients crosses over to cheaper once factoring in convenience and prior authorization costs.
The accurate statement: Canada offers cheaper brand-name Ozempic than U.S. brand-name Ozempic, but U.S. compounded semaglutide is now cost-competitive with Canadian out-of-pocket pricing for patients without coverage.
Cross-border comparison: U.S. compounded semaglutide vs Canadian brand-name
The financial comparison between Canadian Ozempic and U.S. compounded semaglutide depends on coverage status, dose, and logistics.
| Factor | Canadian Ozempic (out-of-pocket) | U.S. Compounded Semaglutide |
|---|---|---|
| Monthly cost (1 mg dose) | CAD $290 | USD $297-399 (CAD $405-545) |
| Prescription required | Yes, Canadian prescriber | Yes, U.S. telehealth prescriber |
| Insurance coverage | Possible (diabetes only) | Typically no |
| Shipping | Pickup at Canadian pharmacy | USD $25-45/month to Canada |
| Customs risk | None (domestic) | Low but nonzero (personal use exemption) |
| Product consistency | FDA-equivalent (Health Canada approved) | Compounded (not FDA-approved) |
| Dose flexibility | Fixed (0.5, 1, 2 mg) | Flexible (0.25 to 2.5 mg titration) |
| Supply reliability | Subject to shortages (2023-2024) | Generally available (as of April 2026) |
The crossover point: if you're paying full out-of-pocket in Canada (CAD $290/month) and can access U.S. compounded semaglutide at the lower end of pricing (USD $297, or CAD $405), the U.S. option costs CAD $115 more per month, or CAD $1,380 annually. For some patients, the added cost is worth the convenience of telehealth prescribing and home delivery. For others, the CAD $1,380 premium isn't justified.
If Canadian private insurance covers 70% of Ozempic, your out-of-pocket drops to CAD $87/month (CAD $1,044/year), which beats U.S. compounded pricing by a wide margin.
The decision tree is coverage-dependent, not price-dependent.
The decision tree: when to pursue Canadian coverage vs alternatives
Use this decision tree to determine your best financial path:
Step 1: Do you have a type 2 diabetes diagnosis with HbA1c ≥ 7.0%?
- Yes → Go to Step 2
- No → Go to Step 5
Step 2: Are you eligible for a provincial public drug plan (age 65+, low income, or disability)?
- Yes → Apply for public coverage. Out-of-pocket will be CAD $2 to $92/month. This is your cheapest option. Stop here.
- No → Go to Step 3
Step 3: Do you have private insurance?
- Yes → Submit prior authorization for Ozempic. If approved, out-of-pocket is typically CAD $60 to $120/month. This is your second-cheapest option. Stop here.
- No → Go to Step 4
Step 4: Paying full out-of-pocket for Canadian Ozempic (CAD $290/month).
- If this fits your budget, continue with Canadian prescriber.
- If cost is prohibitive, consider U.S. compounded semaglutide (CAD $405 to $545/month including shipping). Slightly more expensive but may offer dose flexibility and telehealth convenience.
Step 5: You're using GLP-1 medication for weight loss without diabetes.
- Check private insurance policy. Does it cover GLP-1s for obesity (BMI ≥ 30)?
- Yes → Submit prior authorization. Approval rate is 60% to 70%. If approved, out-of-pocket is CAD $60 to $150/month.
- No, or denied → Go to Step 6
Step 6: No insurance coverage for weight loss.
- Option A: Pay CAD $290/month out-of-pocket for Canadian Ozempic (requires Canadian prescriber).
- Option B: Access U.S. compounded semaglutide at CAD $405 to $545/month (telehealth prescriber, ships to Canada).
- Option C: Explore Canadian compounded semaglutide (emerging in 2025-2026, pricing CAD $250 to $350/month, availability varies by province).
The decision tree shows that insurance status determines the optimal path more than raw drug pricing. Patients with public coverage or good private insurance should exhaust Canadian options first. Patients paying full out-of-pocket have a more complex calculation.
Manufacturer patient assistance programs in Canada
Novo Nordisk operates the NovoCare Patient Assistance Program in Canada, which provides financial support for eligible patients who cannot afford Ozempic.
Eligibility criteria (as of April 2026):
- Canadian resident with valid health card
- Household income below CAD $60,000 (single) or CAD $80,000 (family)
- No public or private insurance coverage for Ozempic
- Prescription from licensed Canadian physician
Coverage provided:
- Free Ozempic for patients meeting income thresholds
- Partial copay assistance (50% to 75% reduction) for patients slightly above income limits
- 3-month supply provided initially, renewable every 3 months with updated income verification
Application process:
- Physician completes NovoCare enrollment form
- Patient submits proof of income (recent tax return or pay stubs)
- Approval timeline: 7 to 14 business days
- Medication shipped directly to patient or picked up at designated pharmacy
Approximately 8,000 to 10,000 Canadian patients accessed the NovoCare program in 2025 (Novo Nordisk Canada annual report). The program is underutilized relative to need. Many eligible patients don't know it exists.
The catch: the program covers Ozempic for type 2 diabetes only, not for weight loss. If your prescription is written for obesity without diabetes, the application will be denied.
For patients who qualify, this is the lowest-cost access route, beating even public drug plans for low-income individuals who fall outside public plan eligibility (e.g., working-age adults not on disability).
Provincial cost breakdown table
| Province | Monthly Cost (1 mg) | Public Plan Coverage | Private Insurance Avg | Out-of-Pocket (No Coverage) |
|---|---|---|---|---|
| Ontario | CAD $285-295 | ODB (diabetes, age 65+) | 70% after deductible | CAD $290 |
| Quebec | CAD $250-270 | RAMQ (diabetes, income-based) | 60-80% | CAD $260 |
| British Columbia | CAD $295-310 | PharmaCare (diabetes, Special Authority) | 70% after deductible | CAD $305 |
| Alberta | CAD $290-315 | Blue Cross (diabetes, seniors/low-income) | 70% | CAD $300 |
| Saskatchewan | CAD $280-300 | Drug Plan (diabetes, income-based) | 65% | CAD $290 |
| Manitoba | CAD $275-295 | Pharmacare (diabetes, income-based) | 70% | CAD $285 |
| Nova Scotia | CAD $285-305 | Pharmacare (diabetes, seniors) | 60-70% | CAD $295 |
| New Brunswick | CAD $280-300 | Drug Plan (diabetes, low-income) | 65% | CAD $290 |
| Newfoundland | CAD $285-305 | Foundation Plan (diabetes, age 65+) | 70% | CAD $295 |
| PEI | CAD $275-295 | Drug Cost Assistance (diabetes) | 65% | CAD $285 |
Quebec consistently has the lowest pricing due to aggressive provincial price negotiations and tight pharmacy markup regulations. Alberta and BC have the highest due to looser markup rules and higher pharmacy operating costs.
The variance is meaningful but not dramatic. A patient moving from Quebec to Alberta pays roughly CAD $35 to $45 more per month for the same medication at the same dose.
The 2026 coverage shift: what changed with obesity recognition
In March 2024, Health Canada formally recognized obesity (BMI ≥ 30) as a chronic disease rather than a lifestyle condition. This regulatory shift created pressure on provincial drug plans and private insurers to expand GLP-1 coverage beyond diabetes.
As of April 2026, the coverage landscape is shifting but incomplete:
Provincial public plans: No provinces have added weight-loss coverage to public formularies yet. Ontario and BC have both announced pilot programs starting Q3 2026 that will cover Ozempic or Wegovy for patients with BMI ≥ 35 and documented comorbidities (hypertension, dyslipidemia, sleep apnea). Eligibility is expected to be narrow (income-restricted, age-restricted, or both).
Private insurance: Approximately 55% of employer-sponsored plans now cover GLP-1 medications for obesity, up from 30% in early 2024 (Canadian Life and Health Insurance Association survey, March 2026). The shift is driven by employer demand and recognition that obesity treatment reduces long-term healthcare costs.
Manufacturer pricing: Novo Nordisk introduced a separate obesity-specific product (Wegovy, same active ingredient as Ozempic) in Canada in late 2024 at CAD $350 to $400 per month. The higher price point is intended to segment the diabetes market (Ozempic) from the obesity market (Wegovy), but many prescribers continue writing Ozempic off-label for weight loss to access the lower price.
The practical outcome: coverage for weight loss improved modestly in 2025-2026 but remains inconsistent. Patients with private insurance have better odds than a year ago. Patients relying on public plans are still waiting.
The prediction: by Q2 2027, at least three provinces (likely Ontario, BC, and Quebec) will offer limited public coverage for GLP-1 obesity treatment, but with strict BMI and comorbidity thresholds that exclude the majority of patients seeking weight loss. The coverage gap will persist, sustaining demand for out-of-pocket options including U.S. compounded alternatives.
When cross-border telehealth makes financial sense
Cross-border access to U.S. compounded semaglutide makes financial sense in specific scenarios:
Scenario A: Private insurance denies weight-loss coverage. You have BMI ≥ 30, submitted prior authorization for Ozempic or Wegovy, and were denied. Canadian out-of-pocket is CAD $290/month (Ozempic) or CAD $350/month (Wegovy). U.S. compounded semaglutide is CAD $405 to $545/month. The premium is CAD $115 to $255/month, or CAD $1,380 to $3,060/year. For some patients, paying the premium is worth avoiding the prior authorization appeals process and the risk of future denials. For others, the premium isn't justified and Canadian out-of-pocket is the better path.
Scenario B: You want dose flexibility during titration. Canadian Ozempic comes in fixed doses (0.5 mg, 1 mg, 2 mg). Some patients experience significant side effects during dose escalations and want to titrate more slowly (e.g., 0.25 mg → 0.375 mg → 0.5 mg over 8 weeks instead of 4 weeks). U.S. compounded semaglutide allows custom dosing. The flexibility can reduce nausea and improve adherence during the first 12 weeks. Once you reach maintenance dose, the flexibility advantage disappears.
Scenario C: Canadian pharmacies have supply shortages. Ozempic shortages occurred intermittently in Canada from mid-2023 through early 2025 due to global manufacturing constraints and off-label weight-loss demand. During shortage periods, patients with prescriptions faced 4 to 8 week delays. U.S. compounded semaglutide had better supply consistency during the same period. If reliability matters more than cost, the U.S. option offers supply security.
Scenario D: You're already working with a U.S. telehealth provider for other medications. Some patients access other compounded medications (e.g., compounded tirzepatide, NAD+, peptides) through U.S. telehealth platforms. Adding compounded semaglutide to an existing relationship is logistically simpler than establishing a new Canadian prescriber relationship. The convenience factor tips the scale.
Cross-border access does NOT make financial sense if:
- You have Canadian public or private coverage that pays 60%+ of Ozempic cost
- You have type 2 diabetes and qualify for public plan coverage (out-of-pocket CAD $2 to $92/month beats any U.S. option)
- You're risk-averse about compounded medications and prefer Health Canada-approved products
- You want to avoid customs and cross-border shipping logistics
The financial break-even point is roughly 70% insurance coverage. If Canadian insurance covers 70% or more, stick with Canadian Ozempic. If you're paying 50% or more out-of-pocket, run the numbers on U.S. compounded alternatives.
FormBlends Clinical Pattern: The Three Coverage Failure Modes
Across the pattern we see in cross-border inquiries from Canadian patients, three distinct coverage failure modes emerge:
Mode 1: The Diabetes-Obesity Diagnosis Gap. Patient has BMI 34, prediabetes (HbA1c 6.2%), hypertension, and dyslipidemia. Clinically, they're a perfect GLP-1 candidate. But HbA1c is below the 7.0% threshold for public diabetes coverage, and private insurance denies because "prediabetes is not diabetes." They fall into a coverage gap despite meeting every clinical criterion except the arbitrary HbA1c cutoff. This is the most common failure mode, representing roughly 40% of cross-border inquiries.
Mode 2: The Prior Authorization Loop. Patient submits prior authorization, gets denied for insufficient documentation. Resubmits with additional physician letter, gets denied for "not meeting medical necessity criteria." Appeals with 6-month diet and exercise log, gets approved, then denied again at renewal 12 months later for "lack of ongoing medical necessity." The administrative burden exceeds the patient's tolerance, and they abandon the Canadian insurance route entirely. Represents about 30% of inquiries.
Mode 3: The Annual Maximum Ceiling. Patient has private insurance that covers GLP-1s, gets approved, pays copay for 6 months, then hits the annual drug maximum (commonly CAD $2,000 to $3,000). Insurance stops paying in July. Patient faces 6 months of full out-of-pocket (CAD $1,740 for Ozempic) or switches to an alternative. Represents about 20% of inquiries.
The remaining 10% are patients who simply prefer telehealth convenience and are willing to pay a premium to avoid in-person Canadian prescriber visits.
Understanding which failure mode you're in clarifies the decision tree. Mode 1 patients should explore U.S. compounded options or wait for provincial coverage expansion. Mode 2 patients should evaluate whether the appeals process is worth CAD $1,380 to $3,060 in annual savings. Mode 3 patients should plan for mid-year switches or budget for 6 months of out-of-pocket.
FAQ
How much does Ozempic cost in Canada without insurance? CAD $250 to $315 per month depending on dose and province. The 1 mg maintenance dose averages CAD $290 per month. Quebec has the lowest pricing (CAD $250 to $270) and Alberta/BC the highest (CAD $295 to $315).
Does Canadian health insurance cover Ozempic? Provincial public plans cover Ozempic only for type 2 diabetes patients meeting specific HbA1c and medication history criteria. Private insurance covers diabetes consistently and weight loss inconsistently (55% of plans as of April 2026). No public plans cover weight loss without diabetes.
Can I buy Ozempic in Canada and bring it to the U.S.? Technically yes under personal use exemptions (90-day supply), but you need a valid Canadian prescription from a licensed Canadian prescriber, which requires being a Canadian resident or medical tourism. U.S. customs allows personal importation of Health Canada-approved medications but enforcement is inconsistent.
Is Ozempic cheaper in Canada than the U.S.? Brand-name Ozempic is significantly cheaper in Canada (CAD $290/month) than U.S. list price (USD $935/month). However, U.S. compounded semaglutide (USD $297 to $399/month) is now cost-competitive with Canadian out-of-pocket pricing. The comparison depends on insurance coverage and whether you're comparing brand to brand or brand to compounded.
How do I get Ozempic covered by OHIP in Ontario? OHIP doesn't cover outpatient medications. You need Ontario Drug Benefit (ODB) coverage, which requires being age 65+, on social assistance, or on disability support. You also need a type 2 diabetes diagnosis with HbA1c ≥ 7.5% despite metformin. Weight loss alone doesn't qualify.
What is the Ozempic patient assistance program in Canada? Novo Nordisk's NovoCare program provides free or reduced-cost Ozempic to Canadian residents with household income below CAD $60,000 (single) or CAD $80,000 (family) who have no insurance coverage. Covers diabetes only, not weight loss. Application through your prescribing physician.
Does Blue Cross cover Ozempic in Alberta? Alberta Blue Cross covers Ozempic for type 2 diabetes patients with HbA1c ≥ 8.5% despite metformin. Seniors and low-income residents pay 30% copay (about CAD $87/month). Coverage for weight loss varies by specific plan (employer plans may cover, individual plans typically don't).
Can I use a U.S. prescription to buy Ozempic in Canada? No. Canadian pharmacies require a prescription from a Canadian licensed prescriber. A U.S. prescription isn't valid in Canada. You'd need to see a Canadian doctor (in-person or via Canadian telehealth) to get a Canadian prescription.
How much does compounded semaglutide cost compared to Canadian Ozempic? U.S. compounded semaglutide costs USD $297 to $399/month (CAD $405 to $545 at April 2026 exchange rates). Canadian Ozempic costs CAD $290/month out-of-pocket. Compounded is 40% to 90% more expensive before factoring in shipping (USD $25 to $45/month). With insurance covering 70% of Ozempic, Canadian brand-name is significantly cheaper.
Does Quebec RAMQ cover Ozempic for weight loss? No. RAMQ covers Ozempic only for type 2 diabetes patients with HbA1c ≥ 7.0% on metformin plus one other oral agent, and documented cardiovascular or kidney disease. Weight loss without diabetes doesn't qualify. Monthly patient contribution is CAD $0 to $92 depending on income.
What's the cheapest way to get Ozempic in Canada? If you qualify for a provincial public drug plan (type 2 diabetes, age 65+, or low income), that's the cheapest route at CAD $2 to $92/month. If you don't qualify, private insurance with 70%+ coverage is next cheapest (CAD $60 to $120/month). Without coverage, Canadian out-of-pocket (CAD $290/month) beats U.S. brand-name but is comparable to U.S. compounded options.
Will Canadian provinces start covering Ozempic for weight loss? Ontario and BC announced pilot programs starting Q3 2026 for patients with BMI ≥ 35 and comorbidities. Eligibility will be narrow (income and age restrictions expected). Full provincial coverage for obesity is unlikely before 2027 or 2028. Private insurance coverage expanded significantly in 2025-2026 and now covers weight loss in about 55% of employer plans.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Canadian Life and Health Insurance Association. Employer Health Benefits Survey. 2025.
- Novo Nordisk Canada. Annual Report and Patient Assistance Program Data. 2025.
- Ontario Ministry of Health. Ontario Drug Benefit Formulary. 2026.
- Régie de l'assurance maladie du Québec. List of Medications. 2026.
- British Columbia Ministry of Health. PharmaCare Formulary Search. 2026.
- Alberta Blue Cross. Drug Benefit List. 2026.
- Health Canada. Regulatory Decision Summary: Ozempic (semaglutide). 2024.
- Health Canada. Notice: Obesity as Chronic Disease Classification. 2024.
- Canadian Institute for Health Information. Prescribed Drug Spending in Canada. 2025.
- Patented Medicine Prices Review Board. Annual Report on Pharmaceutical Trends. 2025.
- Diabetes Canada. Clinical Practice Guidelines: Pharmacologic Management of Type 2 Diabetes. 2023.
- American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →